期刊文献+

正常核型骨髓增生异常综合征患者的基因变异谱系分析 被引量:1

Mutation analysis of 77 patients with normal-karyotype myelodysplastic syndrome
原文传递
导出
摘要 目的 探讨正常核型的骨髓增生异常综合征(myelodysplastic syndrome,MDS)患者多个肿瘤基因的变异情况.方法 应用高通量DNA测序技术检测49种靶基因;采用基因组DNA-PCR联合Sanger测序法检测CALR基因第9外显子、NPM1基因第12外显子、FLT3-ITD及CEBPA的TAD、BZIP两个功能结构域的变异.结果 77例患者中,总的基因变异发生率为80.5%(62/77),其中,43.7%的患者至少携带≥3种基因变异,每例患者平均发生2.21个基因变异.基因变异检出率由高到低依次为RUNX1(23.4%,18/77)、ASXL1(18.2%,14/77)、NPM1(15.6%,12/77)、U2AF1(15.6%,12/77)、DNMT3A(11.7%,9/77)、BCOR(11.7%,9/77)、TET2(10.4%,8/77).SF3B1变异的中位年龄明显大于ASXL1变异者,差异有统计学意义(P=0.023),DNMT3A变异的血小板中位水平高于BCOR变异者(P=0.02);基因变异个数及常见基因变异率在年龄<60岁及≥60岁组中的差异无统计学意义(P均>0.05).67例有效随访患者中,20例发生白血病转化,平均转化时间为5.3个月,其中,RUNX 1、U 2AF 1、FLT3基因变异与转白率呈显著正相关(r分别为0.233、0.232、0.245,P<0.05).结论 正常核型MDS患者多基因变异共存发生率较高,其中,部分基因变异与年龄及白血病转化有一定相关性. Objective To carry out mutation analysis for patients with myelodysplastic syndromes(MDS)and a normal karyotype.Methods Targeted capture and next-generation sequencing(NGS)was carried out using a customized 49-gene panel.FLT3 internal tandem duplication(FLT3-ITD),CALR,NPM1 and CEBPA mutations were detected by PCR and Sanger sequencing.Results Sixty two patients(80.5%)were found to harbor at least one mutation.Each patient has carried 2.21 mutations in average.Coexistence of≥3 mutations was common(43.7%).The most commonly mutated genes were RUNX1(23.4%,18/77),ASXL1(18.2%,14/77),NPM1(15.6%,12/77),U2AF1(15.6%,12/77),DNMT3A(11.7%,9/77).Patients with SF3B1 mutations were significantly older than those with ASXL1 mutations(P=0.023).Mutations of the DNMT3A gene were significantly associated with the blood platelet level compared with BCOR mutations(P=0.02).No significant difference was found in the number and rate of mutations between those under or above 60-year-old.Among 67 patients with clinical follow-up,20(29.8%)has transformed to acute myeloid leukemia,and the time of transformation has ranged from 1&nbsp;to 44 months,with a average of 5.3 months.RUNX1,U2AF1 and FLT3 mutations are associated with leukemic transformation.Conclusion Coexistence of≥3 mutations are frequent among patients with normal-karyotype MDS.Certain mutations are associated with age and leukemic transformation.
作者 秦伟 陈梅玉 蔡晓辉 晁红颖 刘洁 姜乃可 周民 卢绪章 陈苏宁 张日 何川 王谦 Qin Wei;Chen Meiyu;Cai Xiaohui;Chao Hongying;Liu Jie;Jiang Naike;Zhou Min;Lu Xuzhang;Chen Suning;Zhang Ri;He Chuan;Wang Qian(Department of Hematology,the Affiliated Changzhou Second Hospitalof Nanjing Medical University,Changzhou,Jiangsu 213003,China;Jiangsu Provincial Institute of Hematology,Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health,the First Affiliated Hospital of Suzhou University,Suzhou,Jiangsu 215006,China)
出处 《中华医学遗传学杂志》 CAS CSCD 2019年第9期857-861,共5页 Chinese Journal of Medical Genetics
基金 国家自然科学基金青年基金(81500103) 江苏省自然科学基金面上项目(BK-20160283) 常州市科技局项目(CZ20140018).
关键词 骨髓增生异常综合征 基因变异 正常核型 Myelodysplastic syndromes Gene landscape Normal karyotype
  • 相关文献

参考文献2

二级参考文献48

  • 1Guo JU, Su Y, Zhong C, et al. Hydroxylation of 5 methylcytosine by TET1 promotes active DNA demethylalion in the adult brain. Cell, 2011, 145.. 423 434.
  • 2He YF, I.i BZ, I.i Z, et al. Tet-mediated formation of 5 carboxyleytosine and its excision by TDG in mammalian DNA. Science, 2011, 333:1303-1307.
  • 3Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5 hydroxymethylcytosine in embryonic stem cells. Nalure, 2011, 473:394-397.
  • 4Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European Leukemia Net risk classification of acute myeloid leukemia: a Cancer and Leukemia Group Bstudy. J ClinOneol, 2011, 29:1373-1381.
  • 5Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med, 2011, 364 :2496-2506.
  • 6Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res, 2010, 70: 447-452.
  • 7Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia, 2009, 23: 905- 911.
  • 8Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 2011, 25:1147-1152.
  • 9Sekeres MA,Tiu RV,Komrokji R, et al. Phase 2 study of the lenalidomide and azaeitidine combination in patients with higher- risk myelodysplastic syndromes. Blood, 2012, 120:4945-4951.
  • 10Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: aphase2 trial. Blood, 2011, 118:3824-3831.

共引文献11

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部